- Home
- ECBK vs KROS Comparison
ECBK vs KROS Comparison
Compare ECBK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | KROS |
|---|---|---|
| Founded | 1919 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 206.0M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ECBK | KROS |
|---|---|---|
| Price | $21.12 | $11.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 6.5K | ★ 186.0K |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 95.83 | ★ 146.00 |
| EPS | ★ 0.77 | N/A |
| Revenue | $598,000.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.16 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $9.69 |
| 52 Week High | $21.78 | $22.55 |
Technical Indicators
Market Signals| Indicator | ECBK | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 57.56 |
| Support Level | $20.03 | $10.68 |
| Resistance Level | $21.06 | $12.65 |
| Average True Range (ATR) | 0.61 | 0.50 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 67.82 | 70.34 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.